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We have developed sensitive assays for viremia and cell-associated human immunodeficiency
virus type 1 (HIV-1) RNA and DNA to assess the predictive value of virological parameters
determined in blood for virus load in lymph nodes (LNs). Eighteen patients were included;
13 received stavudine/didanosine/hydroxyurea and 5 stavudine/didanosine, and all had viremia
!500 copies/mL for 13 months. At the time of LN biopsy (median, 10 months), the median
viremia was 2.09 log copies/mL (range, !0.70–3.34). Cell-associated HIV-1 RNA and DNA
were detectable in blood and LNs of all patients. The median cell-associated RNA and DNA
were 2.16 log copies/106 cells and 2.60 log copies/106 cells in blood versus 4.31 log RNA copies/
106 cells and 3.26 log DNA copies/106 cells in LNs. Regression analysis shows that, in treated
patients with sustained low viremia, cell-associated RNA and DNA in blood are better pre-
dictors of virus load in LNs than viremia.
The virological response in human immunodeficiency virus
type 1 (HIV-1)–infected patients on antiretroviral therapy is
routinely assessed by the measurement of plasma HIV-1 RNA.
Because lymphoid tissue is the main site of production and
storage of the virus [1], lymph node biopsies have been used
to evaluate residual virus load in patients with low or unde-
tectable viremia [2–4]. In several studies, viremia below the limit
of detection (LOD), that is, !500 or !50 copies/mL, was as-
sociated with a marked decrease of viral deposits in follicular
denditric cells (FDCs) and in cells producing HIV-1 RNA in
lymph nodes [2–7]. However, in most instances, HIV-1 RNA
was still detectable in lymph nodes of patients with viremia
below detection limits, indicating that complete clearance of
HIV-1–producing cells was not achieved [3, 5, 7].
Lymph node biopsy is a surgical procedure that cannot be
often repeated, whereas alternative procedures (i.e., needle as-
piration of lymph node cells) provide an insufficient number of
cells for in-depth virological evaluation, in particular in patients
Received 30 November 1998; revised 9 April 1999; electronically published
4 August 1999.
Presented in part: 12th World AIDS Conference, Geneva, Switzerland,
June 1998.
All patients included in this study have signed the informed consent form
approved by the local ethical committee.
Grant support: Swiss National AIDS Research Program (3100.052403.97)
and the Swiss HIV Cohort Study.
a Members listed after the text.
Reprints or correspondence: Professor Luc Perrin, Laboratory of Virol-
ogy, Geneva University Hospital, 1211 Geneva 14, Switzerland (luc.perrin@
hcuge.ch).
The Journal of Infectious Diseases 1999;180:850–3
q 1999 by the Infectious Diseases Society of America. All rights reserved.
0022-1899/1999/18003-0038$02.00
with low viremia [8]. In contrast, peripheral blood mononuclear
cells (PBMC) are easily accessible. We have thus developed
highly sensitive assays for viremia and cell-associated HIV-1
RNA and DNA to assess the predictive value of virological
parameters determined in blood for virus load in lymph nodes.
In the present investigation, this approach was evaluated in a
cross-sectional study including treated patients with viremia
!500 RNA copies/mL.
Methods
Patients. Patients were participants in a randomized, con-
trolled clinical trial examining the effect of the adjunction of hy-
droxyurea, 500 mg every 12 h, to didanosine, 200 mg every 12 h,
plus stavudine, 40 mg every 12 h [9]. Patients included in this
virological substudy were selected according to the following cri-
teria: at least 6 months of therapy and plasma HIV-1 RNA !500
copies/mL for at least 3 months. Lymph node biopsy was proposed
to the 24 patients fulfilling these criteria; 18 signed the informed
consent form approved by the local ethical committee.
Lymph node biopsies. Inguinal biopsy was performed under
local anesthesia. Only 40% of the patients had palpable lymph
nodes; the inguinal area was selected because local exploration
there is easier than in other locations. Lymph node tissue was
minced with a scalpel in tissue culture medium, and the cells were
teased out by use of small tweezers. The lymph node mononuclear
cells (LNMC) were isolated by gradient centrifugation (Ficoll Hy-
paque; Pharmacia, Dubendorf, Switzerland), and aliquots of
cells were stored in liquid nitrogen.62 3 10
Viremia quantitation. Plasma HIV-1 RNA was quantified first
by use of the standard Amplicor HIV Monitor, version 1.5 (Roche
Diagnostics, Basel, Switzerland). The samples with RNA !500 cop-
ies/mL were retested by use of a modified version of Amplicor HIV
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Table 1. Virological and immunological parameters in lymph node and peripheral
blood.
Parameter Peripheral blood Lymph node Pa
Viremia (log RNA copies/mL) 2.09 (0.70–3.34) — —
Cell-associated RNA (log copies/106 cells) 2.16 (0.70–3.14) 4.31 (1.23–5.27) !.001
Cell-associated DNA (log copies/106 cells) 2.60 (0.78–3.45) 3.26 (2.06–3.79) !.001
CD4 cells (%) 26 (15–38) 48 (25–59) !.001
CD8 cells (%) 50 (31–64) 26 (14–46) !.001
Ratio CD4/CD8 0.55 (0.26–1.23) 1.98 (0.78–3.36) !.001
NOTE. Values are median (range).
a Paired Wilcoxon test.
Monitor assay [10]. Briefly, 1 mL of plasma was centrifuged at
50,000 g for 80 min at 47C. After removal of plasma, the next steps
were performed according to the manufacturer’s instructions, with
the exception of a reduction (7.33) in the input of internal quan-
titative standard (IQS) and in the volume of specimen diluent (55
vs. 400 mL) and a prolongation to 15 min of the substrate incu-
bation step. The LOD is 5 RNA copies/mL, and the mean coef-
ficient of variation is 40% (range, 23%–52%). A value of 5 HIV-1
RNA copies/mL (0.70 log) was attributed to patients with HIV-1
RNA below the LOD.
Cell-associated HIV-1 RNA and DNA quantitation. PBMC
were isolated from 7 mL of EDTA blood by gradient centrifugation
(Ficoll Hypaque; Pharmacia). Cell-associated HIV-1 RNA and
DNA were measured on the same cell aliquot by use of the reagents
of the Amplicor HIV-1 Monitor assay (Roche Diagnostics). Pellets
of PBMC or LNMC were lysed in 600 mL of lysis con-62 3 10
taining RNA IQS at 50% of the concentration recommended. After
adding 600 mL of 100% isopropanol, half of the lysate was trans-
ferred into a new tube for RNA quantitation, and the 2 tubes were
centrifuged at 16,000 g for 15 min. After ethanol washing, nucleic
acids were resuspended in 20 mL of buffer containing 10 mM Tris-
HCl at pH 7.4, 5 mM MgCl2, 50 mM KCl, and 0.5 mM CaCl2.
For cell-associated HIV-1 RNA quantitation, the nucleic acid
preparation was incubated for 1 h at 377C with 20 units of DNase
I RNase-free (Boehringer, Mannheim, Germany), then for 5 min
at 957C, and diluted in 80 mL of specimen diluent. Then 50 mL of
RNA preparation, corresponding to cells, was amplified56.25 3 10
according to manufacturer’s instructions by use of primers located
in the gag gene.
For cell-associated HIV-1 DNA quantitation, the nucleic acid
preparation was incubated 1 h at 377C with 10 mg of RNase A
DNase-free (Sigma, Buchs, Switzerland) and diluted in 80 mL of
specimen diluent. Then 50 mL of DNA preparation was added to
mastermix buffer containing 25 copies of DNA IQS (Roche Di-
agnostics) and directly amplified, bypassing the reverse transcrip-
tase incubation step. Negative controls included PBMC from nor-
mal blood donors. Results are expressed in log10 HIV-1 RNA or
DNA copies/106 PBMC or LNMC.
The mean coefficient of variation, evaluated by use of dilutions
of the 8E5 LAV cell line, was 12% (range, 3%–26%) for cell-as-
sociated RNA and 18% (range, 2%–29%) for cell-associated DNA.
The LOD of cell-associated RNA was approximately 3 RNA cop-
ies/106 cells (9/9 replicates containing 10 and 3.3 RNA copies/106
PBMC and 4/6 replicates containing 1.1 RNA copies/106 PBMC
were found to be positive). The LOD of cell-associated DNA was
approximately 5 DNA copies/106 cells (10/10, 8/8, and 4/8 replicates
containing 10, 5, and 2.5 DNA copies/106 PBMC, respectively, were
found to be positive).
Immunological parameters. CD3, CD4, and CD8 lymphocyte
cell counts were determined by flow cytometry (EPICS IV; Coulter,
Nyon, Switzerland) by use of fluoresceinated DAKO-T3, DAKO-
T8, and R-Phycoerythrin DAKO-CD4 (Dako, Glostrup,
Denmark).
Statistical analysis. Associations between parameters were as-
sessed by use of the Spearman rank correlation analysis. Com-
parisons between parameters were done by use of the paired Wil-
coxon-test. Assessment of parameters associated with
cell-associated RNA in lymph node was performed by use of uni-
variate and multivariate linear regression models. To allow for
comparisons between variables, we computed the relative predictive
ability (RPA) of each predictor, that is, the relative percentage of
variance explained, compared with the best predictor. The RPA is
the F-statistic of a predictor divided by the F-statistic of the best
predictor [11].
Results
Patients. Eighteen patients were included; 13 patients re-
ceived didanosine/stavudine/hydroxyurea, and 5 patients re-
ceived didanosine/stavudine/placebo. The median baseline CD4
cell count was 347/mm3 (range, 220–482), and the median
plasma HIV-1 RNA was 4.50 log copies/mL (range, 3.20–5.08).
Lymph node biopsies were performed 6–12 months after treat-
ment initiation (median, 10 months). At the time of lymph node
biopsy, the median CD4 cell count was 512/mm3 (range,
261–648) in blood. The median CD4 cell count change from
before therapy was 1121/mm3 (range, 254 to 1360). The per-
centage of CD4 cells was approximately 2-fold higher in lymph
nodes than in blood (table 1).
Quantitation of cell-associated HIV-1 RNA and DNA. The
median decrease of viremia from before therapy to the time of
lymph node biopsy was 22.08 log RNA copies/mL (range,
23.60 to –1.16). The median time to first viremia !500 RNA
copies/mL was 1 month (range, 1–3), and the median duration
with viremia !500 RNA copies/mL was 5 months (range, 3–11).
Virological parameters measured in blood and lymph nodes
at the time of lymph node biopsy are reported in table 1. The
median plasma RNA was 2.09 log copies/mL. Eight patients
had plasma RNA !50 copies/mL, and 3 of them had !5 copies/
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Table 2. Predictors of cell-associated RNA in lymph node (regression analysis).
Parameter
LNMC RNA changea
(95% CI) P RPA (%)b
Before therapy
Viremia (per 1 log higher) 0.75 (20.05–1.94) .21 8.6
CD4 PBMC (per 100/mm3 higher) 20.40 (21.30–0.40) .33 5.0
CD4/CD8 PBMC ratio (per 0.1 higher) 20.35 (20.89–0.20) .20 8.9
Therapy
Time to first viremia !500 copies/mL (per 1 more month) 20.25 (20.97–0.47) .47 2.6
Duration with viremia !500 copies/mL (per 1 more month) 20.24 (20.51–0.03) .07 18.0
Viremia (per 1 log higher) 0.89 (0.16–1.62) .02 32.3
Change in viremia (per 1 log higher) 0.80 (20.18–1.78) .10 14.5
CD4 PBMC (per 100/mm3 higher) 20.05 (20.60–0.50) .85 0.2
CD4/CD8 PBMC ratio (per 0.1 higher) 20.12 (20.42–0.18) .42 3.4
RNA PBMC (per 1 log higher) 1.41 (0.72–2.09) !.001 92.8
DNA PBMC (per 1 log higher) 1.54 (0.82–2.26) !.001 100
NOTE. LNMC, lymph node mononuclear cell; CI, confidence interval; PBMC, peripheral blood mononuclear
cells.
a Log RNA copies/106 LNMC.
b RPA, relative predictive ability. The RPA is the F-statistic of a predictor divided by the F-statistic of the best
predictor. The best predictor was DNA PBMC (RPA value of 100%).
mL; all were on hydroxyurea. Cell-associated RNA and DNA
were detectable in all patients in both blood and lymph nodes.
Plasma RNA/mL was, on average, 44-fold lower (95% confi-
dence interval [CI], 11- to 174-fold) than LNMC-associated
RNA/106 cells, and PBMC-associated RNA was, on average,
34-fold lower (95% CI, 11- to 107-fold) than LNMC-associated
RNA.
A strong correlation was observed between cell-associated
RNA and DNA in both PBMC ( , ) and LNMCr 5 .80 P ! .001
( , ).There was only a weak correlation betweenr 5 .82 P ! .001
plasma RNA and PBMC-associated RNA ( , )r 5 .42 P 5 .08
or PBMC-associated DNA ( , ). Similarly, a weakr 5 .40 P 5 .10
correlation was observed between plasma RNA and both
LNMC-associated RNA ( , ) and LNMC-asso-r 5 .46 P 5 .05
ciated DNA ( , ). In contrast, a strong correlationr 5 .58 P 5 .02
was found between PBMC-associated RNA and LNMC-as-
sociated RNA ( , ) or LNMC-associated DNAr 5 .67 P 5 .002
( , ).r 5 .78 P ! .001
Parameters predictive of virus load in lymph nodes. In uni-
variate linear regression analysis, plasma RNA, PBMC-asso-
ciated RNA, and DNA determined at the time of lymph node
biopsy significantly predict LNMC-associated RNA (table 2).
Pretherapy plasma RNA, CD4 cell counts, and the CD4/CD8
ratio did not predict LNMC-associated RNA, but the duration
of viremia !500 copies/mL did. To compare predictors, we cal-
culated the relative predictive ability (RPA) for each parameter;
the RPA values of PBMC-associated RNA and DNA were in
the same range and were 3 times higher than that of plasma
RNA.
Discussion
In this investigation, we show that in treated HIV-1 patients
with sustained low viremia, cell-associated RNA and DNA in
blood are better predictors of virus load in lymph nodes than
viremia.
Patients selected for this substudy were included in a clinical
trial assessing the effect of the addition of hydroxyurea to com-
bined therapy with didanosine and stavudine [9]. As reported
previously, the adjunction of hydroxyurea to a didanosine-con-
taining regimen is associated with an additional decrease of
viremia [9, 12]. As the main inclusion criterion for this study
was a viremia level !500 copies/mL for at least 3 months, we
included more patients receiving didanosine/stavudine plus hy-
droxyurea than receiving didanosine/stavudine plus placebo,
precluding comparative analysis.
The 3 parameters evaluated in blood (plasma RNA, cell-
associated RNA, and DNA) had similar levels of absolute sen-
sitivity per unit volume, since approximately PBMC61–3 3 10
are contained in 1 mL of blood. Comparison of plasma RNA
with PBMC-associated RNA indicates a higher sensitivity of
cell-associated RNA, since the 3 patients with plasma RNA !5
copies/mL had detectable PBMC-associated RNA. This sug-
gests that, even in patients with plasma RNA !5 copies/mL,
circulating cells containing HIV-1 RNA persist. These data are
in agreement with previous data showing the persistence of
replication-competent, infected CD4 cells in the blood of pa-
tients on highly active antiretroviral therapy with viremia !50
copies/mL [13].
We found, as previously reported, higher concentrations of
cell-associated RNA in lymph nodes than in blood [2–5]. Sev-
eral factors might explain this observation, including a release
into blood restricted to cells with low levels of replication, rapid
killing in the blood of cells engaged in active viral replication,
impaired T cell functions in lymphoid tissues [14], or impaired
penetration of antiretroviral drugs into lymph nodes. Interest-
ingly, in treated patients with low viremia, only a weak cor-
relation was observed between plasma RNA and LNMC-as-
sociated RNA, whereas a stronger correlation was observed
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between PBMC- and LNMC-associated RNA. Our preliminary
data indicate that in treated patients, PBMC-associated RNA
levels are better indicators of virus load in lymph nodes than
plasma RNA, as confirmed by linear regression analysis. One
likely explanation is that free viruses are rapidly removed from
the blood through trapping in the FDC network and/or mac-
rophages, whereas both acutely and latently infected cells in
blood have a longer half-life [5, 15].
In conclusion, the main finding of this preliminary study is
that the quantitation of cell-associated RNA and DNA in
PBMC provides an excellent estimate of HIV-1 virus load in
lymphoid tissues. These assays may represent in the future new
standards for the assessment of treatment efficacy in patients
with undetectable or low viremia.
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